benazepril
| Per policy, orders for these non-formulary agents will be changed to formulary equivalents. | |
|---|---|
| Non-Formulary Agent | Formulary Equivalent |
| benazepril (Lotensin) 5 mg | lisinopril (Zestril, Prinivil) 5 mg |
| benazepril (Lotensin) 10 mg | lisinopril (Zestril, Prinivil) 10 mg |
| benazepril (Lotensin) 20 mg | lisinopril (Zestril, Prinivil) 20 mg |
| benazepril (Lotensin) 40 mg | lisinopril (Zestril, Prinivil) 40 mg |
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | benazepril (Lotensin) |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | RAS inhibitors (ACEIs ARBs, ARNIs, aliskiren) ⇄ Another RAS inhibitor or a potassium-sparing diuretic |
| Risk Rationale | Increased risk of hyperkalemia. |
| Recommendation | Avoid routinely using 2 or more RAS inhibitors, or a RAS inhibitor and potassium-sparing diuretic, concurrently in those with chronic kidney disease Stage 3a or higher. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |